These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


254 related items for PubMed ID: 8391674

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group.
    Arch Ophthalmol; 1996 Jan; 114(1):23-33. PubMed ID: 8540847
    [Abstract] [Full Text] [Related]

  • 4. 2.5 years survival with sequential ganciclovir/foscarnet treatment in a patient with acquired immune deficiency syndrome and cytomegalovirus retinitis.
    Geier SA, Klauss V, Matuschke A, Kronawitter U, Goebel FD.
    Ger J Ophthalmol; 1992 Jan; 1(2):110-3. PubMed ID: 1335812
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group.
    Ophthalmology; 1994 Jul; 101(7):1250-61. PubMed ID: 8035989
    [Abstract] [Full Text] [Related]

  • 9. Combined intravenous ganciclovir and foscarnet for children with recurrent cytomegalovirus retinitis.
    Walton RC, Whitcup SM, Mueller BU, Lewis LL, Pizzo PA, Nussenblatt RB.
    Ophthalmology; 1995 Dec; 102(12):1865-70. PubMed ID: 9098289
    [Abstract] [Full Text] [Related]

  • 10. Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir.
    Dunn JP, MacCumber MW, Forman MS, Charache P, Apuzzo L, Jabs DA.
    Am J Ophthalmol; 1995 May; 119(5):587-96. PubMed ID: 7733184
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome.
    Kuppermann BD, Flores-Aguilar M, Quiceno JI, Rickman LS, Freeman WR.
    Arch Ophthalmol; 1993 Oct; 111(10):1359-66. PubMed ID: 8216016
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cytomegalovirus optic neuritis: characteristics, therapy and survival.
    Mansor AM, Li HK.
    Ophthalmologica; 1995 Oct; 209(5):260-6. PubMed ID: 8570149
    [Abstract] [Full Text] [Related]

  • 16. Cytomegalovirus retinitis and viral resistance. Prevalence of resistance at diagnosis, 1994. Cytomegalovirus Retinitis and Viral Resistance Study Group.
    Jabs DA, Dunn JP, Enger C, Forman M, Bressler N, Charache P.
    Arch Ophthalmol; 1996 Jul; 114(7):809-14. PubMed ID: 8660163
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.
    Wagstaff AJ, Bryson HM.
    Drugs; 1994 Aug; 48(2):199-226. PubMed ID: 7527325
    [Abstract] [Full Text] [Related]

  • 19. Pathology of cytomegalovirus retinitis treated with sustained release intravitreal ganciclovir.
    Anand R, Font RL, Fish RH, Nightingale SD.
    Ophthalmology; 1993 Jul; 100(7):1032-9. PubMed ID: 8391675
    [Abstract] [Full Text] [Related]

  • 20. Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151.
    Jacobson MA, Kramer F, Bassiakos Y, Hooton T, Polsky B, Geheb H, O'Donnell JJ, Walker JD, Korvick JA, van der Horst C.
    J Infect Dis; 1994 Jul; 170(1):189-93. PubMed ID: 8014496
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 13.